Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Journal: Nature medicine
Published: August 26, 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Journal: Nature medicine
Published: April 24, 2026
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 08, 2026
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Journal: Hepatology (Baltimore, Md.)
Published: December 17, 2025
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Journal: Hepatology (Baltimore, Md.)
Published: December 17, 2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
Journal: Lancet (London, England)
Published: September 05, 2025
Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
Journal: Diabetes, obesity & metabolism
Published: June 01, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
Journal: The New England journal of medicine
Published: May 09, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: Lancet (London, England)
Published: March 24, 2025
HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.
Journal: Clinical and molecular hepatology
Published: February 08, 2025
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Journal: The New England journal of medicine
Published: June 07, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
Journal: Journal of hepatology
Published: April 25, 2024
Last Updated: 09/26/2026